Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Japanese Journal of Radiology
Erschienen in:

11.08.2023 | Original Article

Diagnostic potential of [18F]FDG PET/MRI in non-small cell lung cancer lymph node metastasis: a meta-analysis

verfasst von: Min Zhang, Wenwen Yang, Yuhang Yuan, Zhikang Liu, Xiaolei Yue, Xiong Cao, Biao Han

Erschienen in: Japanese Journal of Radiology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This meta-analysis evaluated the diagnostic accuracy and diagnostic value of [18F]FDG PET/MRI for mediastinal lymph node staging of NSCLC.

Methods

Relevant articles in PubMed, Embase, Web of Science, and the Cochrane Library were searched until January 2023. Research evaluating [18F]FDG PET/MRI for mediastinal lymph node staging of NSCLC was included. Pooled estimates of sensitivity, specificity, PLR, and NLR were calculated by the "Stata" software.

Results

Nine researches were included, containing 618 patients. The pooled sensitivity of [18F]FDG PET/MRI for detecting mediastinal lymph node staging of NSCLC was 0.82 (0.70–0.90), and the pooled specificity was 0.88 (0.82–0.93). PLR and NLR were 7.38 (4.73–11.52) and 0.20 (0.11–0.36), respectively. The AUC value of this imaging modality was 0.92 (0.90–0.94). The post-test probability for [18F]FDG PET/MRI might rise to 88% when the pre-test probability was set at 50%.

Conclusions

We considered [18F]FDG PET/MRI as an effective imaging tool with relatively high specificity and sensitivity. It has great potential to be used in the clinical management of patients in NSCLC who are amenable to early surgery. More studies with large sample sizes in the same direction are needed in future to obtain more reliable evidence-based support.
Literatur
1.
Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127:3029–30.PubMedCrossRef
2.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
3.
4.
Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31:992–1001.PubMedCrossRef
5.
Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–61.PubMedCrossRef
6.
De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45:787–98.PubMedCrossRef
7.
Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg. 1998;66:886–92.PubMedCrossRef
8.
Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995;60:1573–81.PubMedCrossRef
9.
10.
11.
Wang Q, Zhang X, Wei W, et al. PET imaging of lung cancers in precision medicine: current landscape and future perspective. Mol Pharm. 2022;19:3471–83.PubMedCrossRef
12.
Manafi-Farid R, Askari E, Shiri I, et al. [(18)F]FDG-PET/CT radiomics and artificial intelligence in lung cancer: technical aspects and potential clinical applications. Semin Nucl Med. 2022;52:759–80.PubMedCrossRef
13.
Kaseda K. Recent and current advances in FDG-pet imaging within the field of clinical oncology in NSCLC: a review of the literature. Diagnostics (Basel). 2020;10(8):561.PubMedCrossRef
14.
Wu LM, Xu JR, Gu HY, et al. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better? J Surg Res. 2012;178:304–14.PubMedCrossRef
15.
Matoba M, Tonami H, Kondou T, et al. Lung carcinoma: diffusion-weighted mr imaging–preliminary evaluation with apparent diffusion coefficient. Radiology. 2007;243:570–7.PubMedCrossRef
16.
Al-Ibraheem A, Hirmas N, Fanti S, et al. Impact of (18)F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC. BMC Med Imaging. 2021;21:49.PubMedPubMedCentralCrossRef
17.
Kajiyama A, Ito K, Watanabe H, et al. Consistency and prognostic value of preoperative staging and postoperative pathological staging using (18)F-FDG PET/MRI in patients with non-small cell lung cancer. Ann Nucl Med. 2022;36:1059–72.PubMedCrossRef
18.
Sun J, Li Y, Gong F, et al. The diagnostic value of PET/CT for the lymph node metastasis in Asian patients with non-small cell lung cancer: A meta-analysis. Hell J Nucl Med. 2022;25:196–204.PubMed
19.
Zhao L, He ZY, Zhong XN, et al. (18)FDG-PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer: a meta-analysis. Surg Oncol. 2012;21:230–6.PubMedCrossRef
20.
Schmidt-Hansen M, Baldwin DR, Hasler E, et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014;2014:Cd009519.PubMedPubMedCentral
21.
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.PubMedCrossRef
22.
Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350:185–6.PubMedCrossRef
23.
24.
Heusch P, Buchbender C, Köhler J, et al. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med. 2014;55:373–8.PubMedCrossRef
25.
Fraioli F, Screaton NJ, Janes SM, et al. Non-small-cell lung cancer resectability: diagnostic value of PET/MR. Eur J Nucl Med Mol Imaging. 2015;42:49–55.PubMedCrossRef
26.
Ohno Y, Koyama H, Yoshikawa T, et al. Three-way comparison of whole-body MR, coregistered whole-body FDG PET/MR, and integrated whole-body FDG PET/CT imaging: TNM and stage assessment capability for non-small cell lung cancer patients. Radiology. 2015;275:849–61.PubMedCrossRef
27.
Huellner MW, Galiza Barbosa FD, Husmann L, et al. TNM staging of non-small cell lung cancer: comparison of PET/MR and PET/CT. J Nucl Med. 2016;57:21–6.PubMedCrossRef
28.
Lee SM, Goo JM, Park CM, et al. Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT. Eur Radiol. 2016;26:3850–7.PubMedCrossRef
29.
Kirchner J, Sawicki LM, Schaarschmidt BM, et al. Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2018;45:S502.
30.
Ohno Y, Takeshi Y, Takenaka D, et al. Comparison of diagnostic accuracy for TNM stage among whole-body MRI and coregistered PET/MRI using 1.5-T and 3-T MRI systems and integrated PET/CT for non-small cell lung cancer. Am J Roentgenol. 2020;215:1191–8.CrossRef
31.
Kajiyama A, Ito K, Watanabe H, et al. Consistency and prognostic value of preoperative staging and postoperative pathological staging using(18)F-FDG PET/MRI in patients with non-small cell lung cancer. Ann Nucl Med. 2022;36(12):1059–72.PubMedCrossRef
32.
Wang M-L, Zhang H, Yu H-J, et al. An initial study on the comparison of diagnostic performance of 18F-FDG PET/MR and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer: Focus on pleural invasion. Rev Esp Med Nucl Imagen Mol. 2022;42:16–23.PubMed
33.
34.
Pearson FG, DeLarue NC, Ilves R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg. 1982;83:1–11.PubMedCrossRef
35.
Goldstraw P. The role of mediastinoscopic biopsy in preoperative assessment of lung cancer. J Thorac Cardiovasc Surg. 1994;107:309–11.PubMedCrossRef
36.
Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e211S – e250.PubMedCrossRef
37.
38.
Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur Radiol. 2008;18:1077–86.PubMedCrossRef
39.
Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459–65.PubMedCrossRef
40.
Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A, et al. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review. Eur J Nucl Med Mol Imaging. 2021;48:584–91.PubMedCrossRef
41.
42.
Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20:2865–84.PubMedCrossRef
43.
Shen G, Lan Y, Zhang K, et al. Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis. PLoS ONE. 2017;12: e0173104.PubMedPubMedCentralCrossRef
44.
Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122s-s150.PubMedCrossRef
45.
46.
Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845–55.PubMedCrossRef
Metadaten
Titel
Diagnostic potential of [18F]FDG PET/MRI in non-small cell lung cancer lymph node metastasis: a meta-analysis
verfasst von
Min Zhang
Wenwen Yang
Yuhang Yuan
Zhikang Liu
Xiaolei Yue
Xiong Cao
Biao Han
Publikationsdatum
11.08.2023
Verlag
Springer Nature Singapore
Erschienen in
Japanese Journal of Radiology / Ausgabe 1/2024
Print ISSN: 1867-1071
Elektronische ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-023-01477-0

Weitere Artikel der Ausgabe 1/2024

Utility of machine learning for identifying stapes fixation on ultra-high-resolution CT

  • Original Article

Transvaginal approach combined intracavitary and interstitial brachytherapy assisted by transrectal ultrasound: results from 30 patients with locally advanced cervical cancer

  • Open Access
  • Original Article

Fairness of artificial intelligence in healthcare: review and recommendations

  • Open Access
  • Invited Review

Evaluation of the clinical behavior of unclassified renal cell carcinoma and its imaging findings on computed tomography and magnetic resonance imaging based on World Health Organization (WHO) 2022

  • Open Access
  • Original Article

An overview on multimodal imaging for the diagnostic workup of pleural mesothelioma

  • Open Access
  • Invited Review

Clinical application of 18F-fluorodeoxyglucose positron emission tomography/computed tomography radiomics-based machine learning analyses in the field of oncology

  • Open Access
  • Invited Review

Neu im Fachgebiet Radiologie

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

Wenn es darum geht, die technische Qualität eines Mammogramms zu beurteilen, könnten graue Wandfarbe und reduzierte Beleuchtung im Bildgebungsraum von Vorteil sein. Darauf deuten zumindest Ergebnisse einer kleinen Studie hin. 

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Hypoxisch-ischämische Enzephalopathie: Indikatoren für eine ungünstige Prognose

Eine US-amerikanische Studie widmete sich der Identifizierung prognostischer Parameter bei Neugeborenen mit mittelschwerer oder schwerer hypoxisch-ischämischer Enzephalopathie (HIE), die mittels induzierter Hypoxie behandelt wurden. Besonders im 24-Stunden-EEG und der MRT konnten relevante Hinweise gefunden werden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise